S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ablynx NV stock logo
ABLYF
Ablynx
$50.63
$50.63
$12.50
$55.04
$3.81B1.995,063 shsN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$3.47
+0.3%
$4.51
$2.23
$6.89
$586.74M0.812.58 million shs2.01 million shs
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$119.99
+1.7%
$119.23
$99.74
$120.05
$4.72B0.47148,695 shs24,016 shs
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
$0.18
$113.43
$34.53
$114.20
$6.94M2.05891,560 shsN/A
Repligen Co. stock logo
RGEN
Repligen
$157.14
+0.1%
$189.09
$110.45
$211.13
$8.77B1.02536,743 shs386,770 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ablynx NV stock logo
ABLYF
Ablynx
0.00%0.00%0.00%0.00%0.00%
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-1.42%-13.28%-21.18%+11.97%-29.82%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
0.00%0.00%0.00%0.00%0.00%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.00%0.00%0.00%0.00%-99.84%
Repligen Co. stock logo
RGEN
Repligen
-2.44%-10.80%-20.95%-11.77%-8.38%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
1.9283 of 5 stars
3.40.00.00.02.85.00.0
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/AN/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
4.292 of 5 stars
3.41.00.04.52.62.51.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.71
Moderate Buy$12.94277.19% Upside
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
2.89
Moderate Buy$196.7024.92% Upside

Current Analyst Ratings

Latest ONCE, ALLO, ABLYF, RGEN, and CBPO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2024
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
3/15/2024
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00
2/27/2024
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $8.00
2/22/2024
Repligen Co. stock logo
RGEN
Repligen
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$165.00 ➝ $207.00
2/15/2024
Repligen Co. stock logo
RGEN
Repligen
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$210.00 ➝ $220.00
1/19/2024
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ablynx NV stock logo
ABLYF
Ablynx
$62.73M60.74N/AN/A$2.71 per share18.68
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$90K6,444.21N/AN/A$3.04 per share1.13
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$503.70M9.38$5.01 per share23.93$45.09 per share2.66
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
$64.72M0.11N/AN/A$13.15 per share0.01
Repligen Co. stock logo
RGEN
Repligen
$638.76M13.76$2.96 per share53.20$35.31 per share4.46

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ablynx NV stock logo
ABLYF
Ablynx
-$122.67MN/A0.00N/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$327.27M-$2.09N/AN/AN/A-202,366.25%-53.76%-43.24%5/1/2024 (Estimated)
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
$138.81M$4.2833.5227.90N/A27.43%8.32%7.64%N/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
-$78.82M-$2.11N/AN/AN/A-358.41%-59.10%-33.13%N/A
Repligen Co. stock logo
RGEN
Repligen
$41.58M$0.72218.7075.345.276.51%5.00%3.78%5/1/2024 (Confirmed)

Latest ONCE, ALLO, ABLYF, RGEN, and CBPO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Repligen Co. stock logo
RGEN
Repligen
$0.29N/A-$0.29N/AN/AN/A  
3/14/2024Q4 2023
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.47-$0.43+$0.04-$0.35$0.05 million$0.02 million
2/21/2024Q4 2023
Repligen Co. stock logo
RGEN
Repligen
$0.33$0.33N/A$1.12$155.38 million$155.74 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/AN/AN/AN/AN/A
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
N/AN/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ablynx NV stock logo
ABLYF
Ablynx
N/AN/AN/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
12.38
12.38
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
N/A
12.01
10.13
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
0.35
4.67
4.35
Repligen Co. stock logo
RGEN
Repligen
0.26
7.02
5.75

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
34.77%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
88.37%
Repligen Co. stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Ablynx NV stock logo
ABLYF
Ablynx
N/A
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
27.40%
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2.73%
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
6.00%
Repligen Co. stock logo
RGEN
Repligen
1.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ablynx NV stock logo
ABLYF
Ablynx
N/A75.25 millionN/ANot Optionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
232169.09 million122.76 millionOptionable
China Biologic Products Holdings, Inc. stock logo
CBPO
China Biologic Products
2,26939.36 millionN/AOptionable
Spark Therapeutics Inc stock logo
ONCE
Spark Therapeutics
36838.52 millionN/ANo Data
Repligen Co. stock logo
RGEN
Repligen
1,78355.84 million55.17 millionOptionable

ALLO, RGEN, CBPO, ABLYF, and ONCE Headlines

SourceHeadline
Positive Report for Repligen (RGEN) from Craig-HallumPositive Report for Repligen (RGEN) from Craig-Hallum
markets.businessinsider.com - April 19 at 3:20 PM
Federated Hermes Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)Federated Hermes Inc. Cuts Stake in Repligen Co. (NASDAQ:RGEN)
marketbeat.com - April 19 at 8:44 AM
Repligen Corporation Common Stock (RGEN)Repligen Corporation Common Stock (RGEN)
nasdaq.com - April 18 at 8:20 PM
Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98Repligen (NASDAQ:RGEN) Shares Gap Down to $160.98
marketbeat.com - April 18 at 12:37 PM
Repligen to Report First Quarter 2024 Financial ResultsRepligen to Report First Quarter 2024 Financial Results
finance.yahoo.com - April 17 at 8:46 AM
Notable Two Hundred Day Moving Average Cross - RGENNotable Two Hundred Day Moving Average Cross - RGEN
nasdaq.com - April 17 at 1:20 AM
14,600 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Louisiana State Employees Retirement System14,600 Shares in Repligen Co. (NASDAQ:RGEN) Purchased by Louisiana State Employees Retirement System
marketbeat.com - April 16 at 6:51 AM
Cardiff Oncology (NASDAQ:CRDF) and Repligen (NASDAQ:RGEN) Critical ContrastCardiff Oncology (NASDAQ:CRDF) and Repligen (NASDAQ:RGEN) Critical Contrast
americanbankingnews.com - April 16 at 2:40 AM
London & Capital Asset Management Ltd Acquires 6,215 Shares of Repligen Co. (NASDAQ:RGEN)London & Capital Asset Management Ltd Acquires 6,215 Shares of Repligen Co. (NASDAQ:RGEN)
marketbeat.com - April 15 at 11:28 AM
Critical Review: Repligen (NASDAQ:RGEN) vs. Neurocrine Biosciences (NASDAQ:NBIX)Critical Review: Repligen (NASDAQ:RGEN) vs. Neurocrine Biosciences (NASDAQ:NBIX)
americanbankingnews.com - April 15 at 2:32 AM
International Assets Investment Management LLC Grows Position in Repligen Co. (NASDAQ:RGEN)International Assets Investment Management LLC Grows Position in Repligen Co. (NASDAQ:RGEN)
marketbeat.com - April 13 at 5:30 AM
Artisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share AppreciationArtisan Mid Cap Fund Trimmed Repligen Corporation (RGEN) after Share Appreciation
finance.yahoo.com - April 12 at 10:56 AM
Repligen Co. (NASDAQ:RGEN) Shares Bought by Allspring Global Investments Holdings LLCRepligen Co. (NASDAQ:RGEN) Shares Bought by Allspring Global Investments Holdings LLC
marketbeat.com - April 12 at 6:17 AM
Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesRepligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
americanbankingnews.com - April 12 at 2:20 AM
Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from BrokeragesRepligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Brokerages
marketbeat.com - April 12 at 2:17 AM
Repligen Co. (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plcRepligen Co. (NASDAQ:RGEN) Shares Sold by Impax Asset Management Group plc
marketbeat.com - April 9 at 6:39 PM
RBC Capital Remains a Buy on Repligen (RGEN)RBC Capital Remains a Buy on Repligen (RGEN)
markets.businessinsider.com - April 9 at 3:43 AM
Raymond James & Associates Sells 20,495 Shares of Repligen Co. (NASDAQ:RGEN)Raymond James & Associates Sells 20,495 Shares of Repligen Co. (NASDAQ:RGEN)
marketbeat.com - April 7 at 4:19 AM
Repligen Co. (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLCRepligen Co. (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLC
marketbeat.com - April 5 at 12:49 AM
SG Americas Securities LLC Has $1.27 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)SG Americas Securities LLC Has $1.27 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)
marketbeat.com - March 30 at 4:25 AM
Artemis Investment Management LLP Makes New Investment in Repligen Co. (NASDAQ:RGEN)Artemis Investment Management LLP Makes New Investment in Repligen Co. (NASDAQ:RGEN)
marketbeat.com - March 26 at 11:09 AM
Repligen (NASDAQ:RGEN) Trading Down 2.3%Repligen (NASDAQ:RGEN) Trading Down 2.3%
marketbeat.com - March 25 at 3:20 PM
Handelsinvest Investeringsforvaltning Sells 17,821 Shares of Repligen Co. (NASDAQ:RGEN)Handelsinvest Investeringsforvaltning Sells 17,821 Shares of Repligen Co. (NASDAQ:RGEN)
marketbeat.com - March 21 at 6:36 AM
Repligen Appoints Maggie A. Pax to Board of DirectorsRepligen Appoints Maggie A. Pax to Board of Directors
globenewswire.com - March 19 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ablynx logo

Ablynx

OTCMKTS:ABLYF
Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.
Allogene Therapeutics logo

Allogene Therapeutics

NASDAQ:ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
China Biologic Products logo

China Biologic Products

NASDAQ:CBPO
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Spark Therapeutics logo

Spark Therapeutics

NASDAQ:ONCE
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Repligen logo

Repligen

NASDAQ:RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.